Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PRL (Phakic Refractive Lens) implant moves to phase III US myopia trials:

This article was originally published in Clinica

Executive Summary

The US FDA has given Medennium the green light to start phase III trials of its intraocular lens for treating myopia. The Phakic Refractive Lens (PRL) is a posterior chamber device that is inserted in a procedure similar to artificial lens insertion in cataract surgery. Unlike other intraocular lens and implantable contact lenses, the device is not fixated in the eye, says the Irvine, California company. The PRL is already available in Europe, where it is distributed exclusively by CIBA Vision, the eye care unit of Novartis.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts